Company Information

  

Address: 350 FIFTH AVENUE
SUITE 4740 
City: NEW YORK 
State: NY 
Zip Code: 10118 
Telephone: 212-330-8500 

Description of Business

Primary SIC Code: 3841
(As filed with the SEC)  

Daxor Corporation is a medical device manufacturing company which provides additional biotechnology services. Daxor Corporation was originally incorporated in New York State as Iatric Corporation in May 1971 for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. Our principal executive offices are located at 350 Fifth Avenue, Suite 7120, New York, NY 10118. The "Investor Relations" section of our website provides free copies of our annual reports on Form 10-K, our quarterly reports on Form 10-Q, and any current reports on Form 8-K, Forms 3, 4 and 5. For the past 16 years, the Company's major focus has been the creation and development of the BVA-100 ® Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume.  ... More ...  

Per Share Overview

Date 12-mos Rolling EPS Dividend P/E Ratio
12/2011-1.700.100N/E
09/2011-0.82NAN/E
06/20110.790.15012.89
03/20110.88NA11.65
12/20101.170.6507.91

Key Financial Ratios and Statistics

FYE: 12/31

Profitability 2011 Leverage 2011
Net Inc/Comm Equity6.56Total Liab/Total Assets0.58
Net Inc/Total Assets-0.08Total Liab/Inv Cap2.19
Net Inc/Inv Cap-0.32Total Liab/Comm Equity-45.16
Pretax Inc/Net Sales-8.52Interest Coverage RatioNA
Net Inc/Net Sales-4.97Curr Debt/Equity0.38
Cash Flow/Net Sales-4.50LTD/Equity0.01
SG&A/NetSales2.68Total Debt/Equity0.39
Asset Utilization   Liquidity  
Net Receivables Turnover0.05Quick Ratio1.65
Inventory Turnover1.96Current Ratio1.66
Inventory Day Sales0.01Net Rec/Curr Assets0.31
Net Sales/Work Cap0.04Inv/Curr Assets0.00
Net Sales/PP&E0.36  

Income Statement (Millions)

  12/31/2011 9/30/2011 6/30/2011 3/31/2011
Total Revenues(Net Sales) 0.37 0.34 0.36 0.38
Cost of Goods Sold 0.18 0.15 0.16 0.17
Selling & Admin Exps 0.49 0.82 0.87 1.70
Operating Income -1.01 -1.26 -1.34 -2.18
Interest Exp -0.14 0.03 0.08 0.03
Pretax Income -2.55 -7.03 -0.37 -2.39
Other Income -1.51 -5.74 1.06 -0.18
Net Income Bef Extraordinary ... NA NA NA NA
Net Income -1.49 -4.18 -0.18 -1.33

Balance Sheet (Millions)

Assets 12/31/2011 9/30/2011 6/30/2011 3/31/2011
Cash & Short Term Investments 55.86 52.35 54.17 53.26
Receivables - Total 25.31 31.15 37.41 34.70
Inventories - Total 0.30 0.31 0.36 0.39
Total Current Assets 81.69 84.15 92.12 88.51
Net Property, Plant & Equipment 4.00 4.07 4.08 4.12
Total Assets 85.72 88.25 96.24 92.67
Liabilities        
Accounts Payable 28.31 30.64 9.24 9.40
Debt in Current Liabilities 13.81 19.68 9.76 8.67
Total Current Liabilities 49.26 50.37 50.38 46.57
Long-Term Debt 0.24 0.26 0.27 0.00
Total Liabilities 49.51 50.63 50.66 46.57
Stockholder's Equity        
Minority Interest NA NA NA NA
Preferred Stock NA NA NA NA
Common Stock 0.05 0.05 0.05 0.05
Retained Earnings 24.74 26.65 30.84 31.65
Treasury Stock -11.83 -11.70 -11.63 -11.60
Total Stockholders' Equity 36.22 37.62 45.58 46.10
Total Liabilities and Stockholders' Equity 85.72 88.25 96.24 92.67

Cash Flow Summary (Millions)

Categories 12/31/2011 9/30/2011 6/30/2011 3/31/2011
Net Cash Provided by Operating Activities -0.99 -0.61 -1.04 -3.86
Net Cash Provided by Investing Activities -8.05 -3.28 0.57 -0.63
Net Cash Provided by Financing Activities 9.07 3.81 0.51 4.51

Annual Summary Data (Millions)

Year Sales Net Income EPS
12/20071.8710.65--
12/20081.7615.12--
12/20091.695.82--
12/20101.584.971.17
12/20111.45-7.19-1.70
Growth Rates-6.22----

Stock Ownership

Type Date(Q,M) No. Owners Shares Held (000s) % Own
Institutional09/30/1781403.52




Report Date : 10/16/2017

Powered By Edgar Online © 2017EDGAR®Online, a division of Donnelley Financial Solutions. EDGAR® is a federally registered trademark of the U.S. Securities and Exchange Commission. EDGAR Online is not affiliated with or approved by the U.S. Securities and Exchange Commission.